Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002274
Status:
COMPLETED
Last Update Posted:
2007-10-02
First Post:
1999-11-02
Brief Title:
A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
An Open Label Study Regimen of Videx 23-Dideoxyinosine ddI in Patients With Acquired Immunodeficiency Syndrome AIDS Exhibiting Significant Deterioration While Taking Zidovudine Retrovir
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this open-label study regimen is to make didanosine ddI available to patients with AIDS who are clinically deteriorating on zidovudine AZT and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 454-999-002 | None | None | None |